Immuron Hires LifeSci Capital to Explore Mergers and Other Deals [VIDEO]

Immuron has named LifeSci Capital as its exclusive financial advisor for a strategic review that could lead to mergers, acquisitions or licensing deals.

By Josua Ferreira -

Key Takeaways

  • Immuron has appointed LifeSci Capital as its exclusive financial advisor to look at ways to maximise shareholder value, announced on 10 November 2026.
  • The options under review include mergers, acquisitions, licensing and other deals, with no limit on what else could be considered.
  • The company warns there is no assurance the process will lead to any deal or other outcome.
  • The move follows an earlier effort, led by Pullan Consulting, to find a licensing partner for the IMM-529 C. diff program, which is ready for a mid-stage human trial.
  • Immuron will not update investors on the process until its Board of Directors approves a specific deal or disclosure is required.
This is a special feature video produced for our partner.

Breaking ASX Alerts Direct to Your Inbox

Join +20,000 subscribers receiving alerts.

Join thousands of investors who rely on StockWire X for timely, accurate market intelligence.

About the Publisher